Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase[1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects.

[2] Benzbromarone is highly effective and well tolerated,[3][4][5][6] and clinical trials as early as 1981 and in April 2008 have suggested it is superior to both allopurinol, a non-uricosuric xanthine oxidase inhibitor, and probenecid, another uricosuric drug.

[2][9] Several analogues of the drug have been developed as CYP2C9 and CYP2C19 inhibitors for use in research.

[10][11] Benzbromarone was introduced in the 1970s and was viewed as having few associated serious adverse reactions.

It was registered in about 20 countries throughout Europe, Asia and South America.